Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis

doi:10.1186/s12885-016-2935-4

CORC > 兰州大学 > 兰州大学 > 公共卫生学院 > 期刊论文

	Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis
	Rong, BX; Cai, XG; Liu, H; Gao, WL; Yang, SY; Rong, BX (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, 48 Fenghao West Rd, Xian 710077, Peoples R China.
刊名	BMC CANCER
	2016-11-14
卷号	16
关键词	Endostar Malignant Pleural Effusions Mpe Meta-analysis Efficacy Safety
ISSN号	1471-2407
DOI	10.1186/s12885-016-2935-4
文献子类	Article
英文摘要	Background: Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE). Methods: We searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials (RCTs) with 1066 patients were included. Results: The overall response rate (ORR) (P < 0.001; odds ratio = 3.58) and disease control rate (DCR) (P < 0.001; odds ratio = 2.97) of Endostar combined with chemotherapeutic agents were significantly higher than those of chemotherapeutic agents alone. In addition, Endostar combined treatment remarkably promoted quality of life (QOL) of patients (P < 0.001; odds ratio = 3.04) compared with that of chemotherapeutic agents alone. Moreover, Endostar combined treatment did not have an impact on the incidence of adverse reactions (AEs) (P < 0.05). Conclusions: The efficacy of Endostar combined chemotherapeutic agents was superior to chemotherapeutic agents alone through thoracic perfusion in treating MPE, which indicated that Endostar could be an effective agent for controlling MPE.
学科主题	Oncology
出版地	LONDON
语种	英语
WOS记录号	WOS:000387618900001
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/189112]
专题	公共卫生学院_期刊论文
通讯作者	Rong, BX (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, 48 Fenghao West Rd, Xian 710077, Peoples R China.
推荐引用方式 GB/T 7714	Rong, BX,Cai, XG,Liu, H,et al. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis[J]. BMC CANCER,2016,16.
APA	Rong, BX,Cai, XG,Liu, H,Gao, WL,Yang, SY,&Rong, BX .(2016).Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.BMC CANCER,16.
MLA	Rong, BX,et al."Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis".BMC CANCER 16(2016).